Patent application number | Description | Published |
20120094924 | NUCLEIC ACID DELIVERY COMPOUNDS - Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell. | 04-19-2012 |
20120107264 | NUCLEIC ACID DELIVERY COMPOUNDS - Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell. | 05-03-2012 |
20150141678 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY - What is described is a compound of formula (1) | 05-21-2015 |
20150239834 | SYMMETRIC IONIZABLE CATIONIC LIPID FOR RNA DELIVERY - What are described are compounds of formulas II, III, and IV. The compound of formula II | 08-27-2015 |
20150239926 | ASYMMETRIC IONIZABLE CATIONIC LIPID FOR RNA DELIVERY - What is described is a compound of formula I | 08-27-2015 |
20150307880 | TRANSTHYRETIN ALLELE SELECTIVE UNA OLIGOMERS FOR GENE SILENCING - This invention provides UNA oligomers for selectively inhibiting V30M TTR expression, which can be used in treating amyloidosis. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis by administering a UNA oligomer to a subject. | 10-29-2015 |
20150307881 | UNA OLIGOMERS HAVING REDUCED OFF-TARGET EFFECTS IN GENE SILENCING - This invention provides UNA oligomers for gene silencing with reduced off-target effects. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and various nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis with reduced off-target effects by administering a UNA oligomer to a subject. | 10-29-2015 |
20150322435 | FORMULATIONS FOR TREATING AMYLOIDOSIS - This invention provides pharmaceutical compositions containing a UNA oligomer targeted to TTR and a pharmaceutically acceptable carrier. The compositions can be used in methods for treating or preventing TTR-related amyloidosis in a primate. The compositions, upon administering a single dose to the primate, can reduce TTR protein in the primate for a period of days to weeks. | 11-12-2015 |